← All trials
NCT02030015
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 1, 2014
- Primary completion
- Mar 1, 2019
- Completion date
- Mar 1, 2019
- First posted
- —
- Last posted
- —
- Enrollment
- 30
- Arms / groups
- 1 / —
- Source
- AACT · pre-existing
Sponsors
- University of MinnesotaLead sponsor
- University of MinnesotaOverall official - principal investigator
- National Institute of Neurological Disorders and Stroke (NINDS)Collaborator
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Collaborator
- National Center for Advancing Translational Science (NCATS)Collaborator
- Lysosomal Disease NetworkCollaborator
- National Institutes of Health (NIH)Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.